Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950135-07-002021
Filing Date
2007-04-02
Accepted
2007-04-02 16:59:10
Documents
8
Period of Report
2006-12-31

Document Format Files

Seq Description Document Type Size
1 MOLECULAR INSIGHT PHARMACEUTICALS, INC. b63998mie10vk.htm 10-K 1252689
2 EX-10.39 EMPLOYMENT AGREEMENT FOR NORMAN D. LAFRANCE b63998miexv10w39.txt EX-10.39 37684
3 EX-14.1 CODE OF ETHICS b63998miexv14w1.txt EX-14.1 55271
4 EX-31.1 SECTION 302 CERTIFICATION OF C.E.O. b63998miexv31w1.htm EX-31.1 8703
5 EX-31.2 SECTION 302 CERTIFICATION OF C.F.O. b63998miexv31w2.htm EX-31.2 8690
6 EX-32.1 SECTION 906 CERTIFICATION OF C.E.O. b63998miexv32w1.htm EX-32.1 5061
7 EX-32.2 SECTION 906 CERTIFICATION OF C.F.O. b63998miexv32w2.htm EX-32.2 5009
8 GRAPHIC b63998mib6399801.gif GRAPHIC 25787
  Complete submission text file 0000950135-07-002021.txt   1410208
Mailing Address 160 SECOND STREET CAMBRIDGE MA 02142
Business Address 160 SECOND STREET CAMBRIDGE MA 02142 617-492-5554
Molecular Insight Pharmaceuticals, Inc. (Filer) CIK: 0001340752 (see all company filings)

EIN.: 043412465 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-33284 | Film No.: 07740011
SIC: 2834 Pharmaceutical Preparations